首页 | 本学科首页   官方微博 | 高级检索  
     

重组人干扰素肌注与干扰素阴道栓联合使用治疗宫颈高危型HPV感染
引用本文:郑占才,张晓宁,赵华英,陈颖. 重组人干扰素肌注与干扰素阴道栓联合使用治疗宫颈高危型HPV感染[J]. 中国性科学, 2011, 20(10): 10-11,13. DOI: 10.3969/j.issn.1672-1993.2011.10.004
作者姓名:郑占才  张晓宁  赵华英  陈颖
作者单位:1. 卫生部北京中日友好医院皮肤病与性病科,北京,100029
2. 卫生部北京中日友好医院妇科实验室,北京,100029
摘    要:
目的:探讨重组人干扰素注射液肌肉注射联合干扰素阴道栓剂治疗宫颈高危型HPV感染的疗效。方法:83例宫颈高危型HPV感染患者以半随机方式分为治疗组和对照组,其中治疗组46例,用重组人干扰素α1b注射液50μg,肌肉注射,每日1次,连续10天为1疗程,然后用重组人干扰素α2b阴道栓每次1粒,隔日1次,9粒为1疗程。以上药物每个月1疗程,连用3个月。对照组37例,不给予药物治疗。结果:治疗结束6个月后复查宫颈高危型HPVDNA,治疗组痊愈率46.34%(19/41),有效率80.49%(33/41);对照组痊愈率16.67%(5/30),有效率53.33%(16/30)。经χ2检验,治疗组的痊愈率、有效率均显著高于对照组(χ2=6.276,0.01
关 键 词:重组人干扰素  宫颈  高危型人乳头瘤病毒

Intramuscular recombinant human interferon combined with interferon vaginal suppository in treatment of cervical HR-HPV infection
ZHENG Zhancai,ZHANG Xiaoning,ZHAO Huaying,CHENG Ying. Intramuscular recombinant human interferon combined with interferon vaginal suppository in treatment of cervical HR-HPV infection[J]. The Chinese Journal of Human Sexuality, 2011, 20(10): 10-11,13. DOI: 10.3969/j.issn.1672-1993.2011.10.004
Authors:ZHENG Zhancai  ZHANG Xiaoning  ZHAO Huaying  CHENG Ying
Affiliation:ZHENG Zhancai1,ZHANG Xiaoning1,ZHAO Huaying1,CHENG Ying2 1 Department of Dermatology,China Japan Friendship Hospital,Beijing 100029,China 2 Laboratory of Obstetrics and gynecology,China
Abstract:
Objectives: To investigate the possible efficacy of combined use of recombinant human interferon α1b injection and interferon α2b vaginal suppository in the treatment of female cervical high risk human papillomavirus ( HR - HPV) infection. Methods: Eighty - three patients with cervical HR - HPV infection were semi - randomly divided into two groups. For the 46 cases in the treatment group, one treatment course includes intramuscular injection of 50μg interferon ctlb once daily for 10 days, combined with the administration of interferon α2b vaginal suppository every other day for 18 days. One treatment course took one month and the whole treatment lasted for three months. The control group received no treatment. Result: Cervical HR - HPV DNA were retcsted six months after the treatment. The curative rate and effective rate in the treatment group were 46.34% ( 19/ 41 )and 80.49% (33/41) respectively, being significantly higher than those in the control group( 16.67% (5/30) and 53.33% (16/30) (Х^2 = 6. 276,0. 01 〈 P 〈 0. 05 ;Х^2 = 5.352,0. 01 〈 P 〈 0.05 ). Conclusion: Intramuscular recombinant human interferon combined with interferon vaginal suppository is an effective method for the treatment of cervical HR - HPV infection.
Keywords:Recombinant human interferon  Cervix uteri  High risk human papillomavirus  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号